about
Emerging intravesical therapies for management of nonmuscle invasive bladder cancerInvestigational therapies for non-muscle invasive bladder cancer.Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.Radical cystectomy for BCG failure: has the timing improved in recent years?
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Risk-adapted use of intravesical immunotherapy.
@en
Risk-adapted use of intravesical immunotherapy.
@nl
type
label
Risk-adapted use of intravesical immunotherapy.
@en
Risk-adapted use of intravesical immunotherapy.
@nl
prefLabel
Risk-adapted use of intravesical immunotherapy.
@en
Risk-adapted use of intravesical immunotherapy.
@nl
P2860
P1433
P1476
Risk-adapted use of intravesical immunotherapy
@en
P2093
Andreas Böhle
Matthew R Braasch
P2860
P304
P356
10.1111/J.1464-410X.2008.07968.X
P433
P577
2008-11-01T00:00:00Z